ETX.L Share News (ETX)

AGM, EGM Calendar - Week Ahead

e-Therapeutics Says First Patient Enrolled In Phase Ib ETS2101 Trial

e-Therapeutics Loss Widens As It Increases Development Spending

e-Therapeutics Believes Drug Discovery Process Producing Higher Yield

UK DIRECTOR DEALINGS SUMMARY: Shanta Gold Non-Executive Sells Stake

DIRECTOR DEALINGS: e-Therapeutics Finance Director Buys 150,000 Shares

E-Therapeutics Appoints Sean Nicholson As Executive Director

e-Therapeutics Loss Widens On Pipeline Development; Chair To Retire

UK MORNING BRIEFING: Deutsche Bank Raises Shell View, Cuts BP

Daily Mail General Trust's Chairman sells £15.91m-worth of shares

Viscount Rothermere, the Chairman of Daily Mail and General Trust, has traded in £15.91m-worth of shares in the multi-media and information company. Selling the stock at 860p a piece, Rothermere benefited from the rise seen in the group's share price this week, which has seen it climbed 5.56%, or

DIRECTOR DEALINGS: e-Therapeutics Finance Chief Buys 100,000 Shares

DIRECTOR DEALINGS: e-Therapeutics Non-Executives Allotted New Shares

e-Therapeutics Loss Widens As It Continues Pipeline Development

LONDON (Alliance News) - e-Therapeutics PLC Monday posted a widened pretax loss for 2013 as it continued to invest and develop its pipeline of products. The pharmaceutical company posted a pretax loss of GBP6.1 million, widened from GBP5.0 million, as it upped its research and development e

UK MIDDAY BRIEFING: Centrica Warns, Barclays Restructures

LONDON (Alliance News) - British gas parent Centrica has issued a profit warning Thursday, blaming the extreme winter weather in the US but mild conditions in the UK, as well as the intense pressure that's been put on energy providers in the UK in recent months by politicians

UK WINNERS & LOSERS: Standard Chartered, Barclays Lead FTSE 100 Risers

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Barclays, up 4.9%. Barclays has detailed plans to shrink its investment bank with a new round